A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis
NCT00106834
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
378
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
Infliximab
Sponsor
Centocor, Inc.